SUMF1 and mucosulfatidosis: In addition, treatment of a previously described primary MSD patient‐derived fibroblast line with a homozygous stop mutation and no FGE expression (FGE p.Ser64Ter; Schlotawa et al, 2019) also did not lead to any increase in ARSA activity (Fig 6D).